Apelin-13: A Promising Biomarker for Multiple Sclerosis?

Area of Science:

• Neuroscience
• Biomarker Discovery
• Immunology

Background:

• Apelin-13 is recognized for its potential neuroprotective properties.
• Emerging research suggests apelin-13 could function as a biomarker for neurological disorders.
• Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.

Purpose of the Study:

• To investigate and compare serum apelin-13 levels in adult patients diagnosed with multiple sclerosis against healthy controls.
• To evaluate the potential of apelin-13 as a diagnostic biomarker for multiple sclerosis.

Main Methods:

• The study included 42 patients with relapsing-remitting MS and 41 healthy controls.
• Demographic data, disease duration, and Expanded Disability Symptom Scale (EDSS) scores were collected.
• Serum apelin-13 levels were quantified using the Enzyme-Linked Immunosorbent Assay (ELISA) method.

Main Results:

• Serum apelin-13 levels were found to be significantly elevated in the multiple sclerosis patient group compared to the healthy control group (P = 0.003).
• No significant correlation was observed between serum apelin-13 levels and EDSS scores or disease duration.

Conclusions:

• The study demonstrates statistically significant higher serum apelin-13 levels in multiple sclerosis patients versus controls.
• Further research with larger cohorts is warranted to establish serum apelin levels as a reliable biomarker for multiple sclerosis.
• Apelin-13's role in MS pathogenesis and its utility as a biomarker require additional investigation.